Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
<b>Objective</b>: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as the most common chronic liver disease, is soon to be the leading indication for liver transplantation; however, the diagnosis may remain occult for decades. There is a need for biomark...
Saved in:
Main Authors: | Jessica M. Rubino, Natalie Yanzi Ring, Krishna Patel, Xiaoqing Xia, Todd A. MacKenzie, Roberta M. diFlorio-Alexander |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/13/1/80 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01) -
Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01) -
Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01) -
Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01) -
FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)